---
title: "Double the ChiNext, amplifying A-share power"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/40307869.md"
description: "$Bosera China ChiNext Index Daily Leveraged (2X) Product (07234.HK)$ChiNext Index (399006.SZ) The ChiNext Index has gained +15.11% year-to-date.List of the performance of the top 20 heavyweight stocks in the Shenzhen ChiNext market: Investment involves risks. Past investment performance may not be indicative of future results. Investors should not base their investment decisions solely on the information contained herein. The above information is for reference only and does not constitute and should not be considered as an offer to subscribe for or sell to anyone. Investors should read the relevant fund's prospectus and product key facts statement in detail before making any investment decision..."
datetime: "2026-04-30T01:55:22.000Z"
locales:
  - [en](https://longbridge.com/en/topics/40307869.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/40307869.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/40307869.md)
author: "[博时国际](https://longbridge.com/en/profiles/16136055.md)"
---

# Double the ChiNext, amplifying A-share power

[$Bosera China Growth Enterprise Market Index Daily Leveraged (2X) Product (07234.HK)](https://longbridge.com/quote/07234.HK)[$Growth Enterprise Market Index (399006.SZ)](https://longbridge.com/quote/399006.SZ)The GEM has gained +15.11% year-to-date.

Performance overview of the top 20 heavyweight stocks in the Shenzhen Growth Enterprise Market:

Investing involves risks. Past investment performance may not be indicative of future results. Investors should not base their investment decisions solely on the information contained in this material. The above information is for reference only and does not constitute and should not be considered as an offer to subscribe or sell to any person. Before making any investment decision, investors should read in detail the relevant fund's prospectus and product key facts statement, including the product features and risk factors. Investors should consider whether the product is suitable for them based on their own investment experience, objectives, financial situation, and risk tolerance. If necessary, seek independent professional advice. The above information has not been reviewed by the Securities and Futures Commission of Hong Kong.

Issued by: Bosera International. No part of this document or any information contained herein may be photocopied, distributed or reproduced without the consent of Bosera International.[$Contemporary Amperex Technology Co., Limited (300750.SZ)](https://longbridge.com/quote/300750.SZ)[$East Money Information Co., Ltd. (300059.SZ)](https://longbridge.com/quote/300059.SZ)[$Inovance Technology Co., Ltd. (300124.SZ)](https://longbridge.com/quote/300124.SZ)[$Zhongji Innolight Co., Ltd. (300308.SZ)](https://longbridge.com/quote/300308.SZ)[$Mindray Bio-Medical Electronics Co., Ltd. (300760.SZ)](https://longbridge.com/quote/300760.SZ)[$Shenzhen Sunwin Communication Co., Ltd. (300502.SZ)](https://longbridge.com/quote/300502.SZ)[$Sungrow Power Supply Co., Ltd. (300274.SZ)](https://longbridge.com/quote/300274.SZ)[$Wens Foodstuff Group Co., Ltd. (300498.SZ)](https://longbridge.com/quote/300498.SZ)

### Related Stocks

- [07234.HK](https://longbridge.com/en/quote/07234.HK.md)
- [399006.CN](https://longbridge.com/en/quote/399006.CN.md)
- [300750.CN](https://longbridge.com/en/quote/300750.CN.md)
- [03750.HK](https://longbridge.com/en/quote/03750.HK.md)
- [300308.CN](https://longbridge.com/en/quote/300308.CN.md)
- [HCCD.SG](https://longbridge.com/en/quote/HCCD.SG.md)